专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20120070870A1 Methods and Molecules for Yield Improvement Involving Metabolic Engineering 审中-公开
标题翻译：涉及代谢工程产量改善的方法与分子
公开(公告)号：US20120070870A1
公开(公告)日：2012-03-22
申请号：US13322383
申请日：2010-06-01
申请人： Jeffrey C. Way , Joseph H. Davis
发明人： Jeffrey C. Way , Joseph H. Davis
IPC分类号： C12P7/64 , C12N9/12 , C12P7/16 , C12P7/42 , C12P7/56 , C12N9/00 , C12N9/06
CPC分类号： C12P7/42 , C07K2319/95 , C12N9/1205 , C12N15/10 , C12N15/67
摘要： The invention features methods and compositions relating to cells that have been engineered to reduce or eliminate proteins having enzymatic activity that interfere with the expression of a metabolic product.
摘要翻译：本发明的特征在于与已被工程化以减少或消除干扰代谢产物表达的具有酶活性的蛋白质相关的细胞的方法和组合物。

2. 发明授权

US06465192B2 Compounds and methods for the inhibition of protein-protein interactions 失效
标题翻译：用于抑制蛋白质 - 蛋白质相互作用的化合物和方法
公开(公告)号：US06465192B2
公开(公告)日：2002-10-15
申请号：US09208665
申请日：1998-12-10
申请人： Jeffrey C. Way
发明人： Jeffrey C. Way
IPC分类号： G01N3353
CPC分类号： G01N33/6845 , C40B30/04 , C40B40/00 , G01N33/68
摘要： Compounds having molecular weights of less than 1500 daltons that non-covalently interact with target proteins and covalently bond to target proteins at amino acid side chains that are not part of enzyme active sites, in which covalently bound portions of the compounds sterically block the binding of the target proteins to other proteins, are disclosed. The compounds react with forward reaction rates at least 100 times faster than the forward reaction rates at which the compounds bond to the side chains of the corresponding free amino acids under physiological conditions. Compositions including these compounds and methods for preparing these compounds are also disclosed.
摘要翻译：分子量小于1500道尔顿的化合物与靶蛋白非共价相互作用，并且在不属于酶活性位点的氨基酸侧链上与靶蛋白共价键合，其中化合物的共价结合部分空间阻断了公开了靶蛋白与其他蛋白质。化合物与正向反应速率反应至少比在生理条件下化合物键合到相应游离氨基酸的侧链的正向反应速率快100倍。还公开了包括这些化合物的组合物和制备这些化合物的方法。

3. 发明申请

US20160108133A1 METHODS AND COMPOSITIONS FOR TREATMENT OF POMPE DISEASE 有权
标题翻译：用于治疗疾病的方法和组合物
公开(公告)号：US20160108133A1
公开(公告)日：2016-04-21
申请号：US14769270
申请日：2014-02-20
申请人： Dustin D. ARMSTRONG , Jeffrey C. WAY , VALERION THERAPEUTICS, LLC
发明人： Dustin D. Armstrong , Jeffrey C. Way
IPC分类号： C07K16/40 , C12N9/26 , A61K9/00 , A61K38/47 , C07K16/44 , A61K47/48
CPC分类号： C07K16/40 , A61K9/0019 , A61K38/00 , A61K38/47 , A61K47/6871 , A61K2039/505 , C07K16/44 , C07K2317/14 , C07K2317/24 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/77 , C07K2317/92 , C07K2317/94 , C07K2319/10 , C07K2319/30 , C07K2319/33 , C07K2319/70 , C12N9/2408 , C12Y302/0102
摘要： In certain embodiments, the present disclosure provides compositions and methods for treating Pompe disease.
摘要翻译：在某些实施方案中，本公开提供了治疗庞培病的组合物和方法。

4. 发明申请

US20090311803A1 Treatment Of Tumors Expressing Mutant EGF Receptors 审中-公开
标题翻译：治疗表达突变型EGF受体的肿瘤
公开(公告)号：US20090311803A1
公开(公告)日：2009-12-17
申请号：US12544495
申请日：2009-08-20
申请人： Jeffrey C. Way , Ginger Chao , Catherine Cresson , Douglas Lauffenburger , K. Dane Wittrup
发明人： Jeffrey C. Way , Ginger Chao , Catherine Cresson , Douglas Lauffenburger , K. Dane Wittrup
IPC分类号： G01N33/566
CPC分类号： C07K16/2863 , A61K2039/505 , C07K2317/34 , C07K2317/567 , C07K2317/77
摘要： The invention discloses methods for identifying antibodies that reduce or prevent signaling by intact epidermal growth factor receptor (EGFR), or mutant EGFRs, such as EGFRvIII.
摘要翻译：本发明公开了用于鉴定减少或预防完整表皮生长因子受体（EGFR）或突变EGFR（如EGFRvIII）的信号传导的抗体的方法。

5. 发明授权

US07615217B2 Artificial proteins with reduced immunogenicity 有权
标题翻译：具有降低免疫原性的人造蛋白
公开(公告)号：US07615217B2
公开(公告)日：2009-11-10
申请号：US11716878
申请日：2007-03-12
申请人： Stephen Gillies , Francis J. Carr , Jones Tim , Graham Carter , Anita Hamilton , Stephen Williams , Marian Hanlon , John Watkins , Matthew Baker , Jeffrey C. Way
发明人： Stephen Gillies , Francis J. Carr , Jones Tim , Graham Carter , Anita Hamilton , Stephen Williams , Marian Hanlon , John Watkins , Matthew Baker , Jeffrey C. Way
IPC分类号： A61K39/395
CPC分类号： C07K16/30 , C07K16/28 , C07K16/2863 , C07K2317/24 , C07K2317/34 , C07K2319/00 , C07K2319/30
摘要： The invention relates to artificial modified proteins, preferably fusion proteins, having a reduced immunogenicity compared to the parent non-modified molecule when exposed to a species in vivo. The invention relates, above all, to novel immunoglobulin fusion proteins which essentially consist of an immunoglobulin molecule or a fragment thereof covalently fused via its C-terminus to the N-terminus of a biologically active non-immunoglobulin molecule, preferably a polypeptide or protein or a biologically active fragment thereof. In a specific embodiment, the invention relates to fusion proteins consisting of an Fc portion of an antibody which is fused as mentioned to the non-immunological target molecule which elicits biological or pharmacological efficacy. The molecules of the invention have amino acid sequences which are altered in one or more amino acid residue positions but have in principal the same biological activity as compared with the non-altered molecules. The changes are made in regions of the molecules which are identified as T-cell epitopes, which contribute to an immune reaction in a living host. Thus, the invention also relates to a novel method of making such fusion proteins by identifying said epitopes comprising calculation of T-cell epitope values for MHC Class II molecule binding sites in a peptide by computer-aided methods.
摘要翻译：本发明涉及人体修饰蛋白，优选融合蛋白，当与体内物种暴露时，与亲本非修饰分子相比具有降低的免疫原性。本发明首先涉及新的免疫球蛋白融合蛋白，其基本上由免疫球蛋白分子或其通过C末端与生物活性非免疫球蛋白分子，优选多肽或蛋白质的N末端共价融合的片段组成，或其生物活性片段。在一个具体的实施方案中，本发明涉及由抗体的Fc部分组成的融合蛋白，所述Fc部分如提及的非免疫靶标分子融合而引起生物学或药理学功效。本发明的分子具有氨基酸序列，其在一个或多个氨基酸残基位置被改变，但与未改变的分子相比具有相同的生物学活性。在被鉴定为T细胞表位的分子的区域中进行改变，其有助于在宿主中的免疫反应。因此，本发明还涉及通过鉴定所述表位来制备此类融合蛋白的新方法，包括通过计算机辅助方法计算肽中MHC II类分子结合位点的T细胞表位值。

6. 发明授权

US07189830B2 Anti-KSA/IL-2 fusion proteins with reduced immunogenicity 有权
标题翻译：抗KSA / IL-2融合蛋白具有降低的免疫原性
公开(公告)号：US07189830B2
公开(公告)日：2007-03-13
申请号：US10468370
申请日：2002-02-18
申请人： Stephen Gillies , Francis J. Carr , Jones Tim , Graham Carter , Anita Hamilton , Stephen Williams , Marian Hanlon , John Watkins , Matthew Baker , Jeffrey C. Way
发明人： Stephen Gillies , Francis J. Carr , Jones Tim , Graham Carter , Anita Hamilton , Stephen Williams , Marian Hanlon , John Watkins , Matthew Baker , Jeffrey C. Way
IPC分类号： C07K14/55 , C12N15/62
CPC分类号： C07K16/30 , C07K16/28 , C07K16/2863 , C07K2317/24 , C07K2317/34 , C07K2319/00 , C07K2319/30
摘要： The invention relates to artificial modified proteins, preferably fusion proteins, having a reduced immunogenicity compared to the parent non-modified molecule when exposed to a species in vivo. The invention relates, above all, to novel immunoglobulin fusion proteins which essentially consist of an immunoglobulin molecule or a fragment thereof covalently fused via its C-terminus to the N-terminus of a biologically active non-immunoglobulin molecule, preferably a polypeptide or protein or a biologically active fragment thereof. In a specific embodiment, the invention relates to fusion proteins consisting of an Fc portion of an antibody which is fused as mentioned to the non-immunological target molecule which elicits biological or pharmacological efficacy. The molecules of the invention have amino acid sequences which are altered in one or more amino acid residue positions but have in principal the same biological activity as compared with the non-altered molecules. The changes are made in regions of the molecules which are identified as T-cell epitopes, which contribute to an immune reaction in a living host. Thus, the invention also relates to a novel method of making such fusion proteins by identifying said epitopes comprising calculation of T-cell epitope values for MHC Class II molecule binding sites in a peptide by computer-aided methods.
摘要翻译：本发明涉及人体修饰蛋白，优选融合蛋白，当与体内物种暴露时，与亲本非修饰分子相比具有降低的免疫原性。本发明首先涉及新的免疫球蛋白融合蛋白，其基本上由免疫球蛋白分子或其通过C末端与生物活性非免疫球蛋白分子，优选多肽或蛋白质的N末端共价融合的片段组成，或其生物活性片段。在一个具体的实施方案中，本发明涉及由抗体的Fc部分组成的融合蛋白，所述Fc部分如提及的非免疫靶标分子融合而引起生物学或药理学功效。本发明的分子具有氨基酸序列，其在一个或多个氨基酸残基位置被改变，但与未改变的分子相比具有相同的生物学活性。在被鉴定为T细胞表位的分子的区域中进行改变，其有助于在宿主中的免疫反应。因此，本发明还涉及通过鉴定所述表位来制备此类融合蛋白的新方法，包括通过计算机辅助方法计算肽中MHC II类分子结合位点的T细胞表位值。

7. 发明授权

US10017581B2 Methods and compositions for treatment of Pompe disease 有权
公开(公告)号：US10017581B2
公开(公告)日：2018-07-10
申请号：US14769270
申请日：2014-02-20
申请人： VALERION THERAPEUTICS, LLC , Dustin D. Armstrong , Jeffrey C. Way
发明人： Dustin D. Armstrong , Jeffrey C. Way
IPC分类号： A61K38/00 , C07K16/40 , C07K16/44 , C12N9/26 , A61K9/00 , A61K38/47 , A61K47/68 , A61K39/00
CPC分类号： C07K16/40 , A61K9/0019 , A61K38/00 , A61K38/47 , A61K47/6871 , A61K2039/505 , C07K16/44 , C07K2317/14 , C07K2317/24 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/77 , C07K2317/92 , C07K2317/94 , C07K2319/10 , C07K2319/30 , C07K2319/33 , C07K2319/70 , C12N9/2408 , C12Y302/0102
摘要： In certain embodiments, the present disclosure provides compositions and methods for treating Pompe disease.

8. 发明授权

US10385367B2 Methods and molecules for yield improvement involving metabolic engineering 有权
公开(公告)号：US10385367B2
公开(公告)日：2019-08-20
申请号：US13322383
申请日：2010-06-01
申请人： Jeffrey C. Way , Joseph H. Davis
发明人： Jeffrey C. Way , Joseph H. Davis
IPC分类号： C12N1/00 , C12N5/00 , C12P13/00 , C12P13/04 , C12P7/42 , C12N9/12 , C12N15/10 , C12N15/67
摘要： The invention features methods and compositions relating to cells that have been engineered to reduce or eliminate proteins having enzymatic activity that interfere with the expression of a metabolic product.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式